Have your competent? doctor test you for this so if found, those non-existent dementia prevention protocols your doctor failed to create will be used to prevent that dementia.
BUT YOUR DOCTOR IS INCOMPETENT! NO PROTOCOLS WERE EVER CREATED!
Get him/her fired then!
Why this testing is needed post stroke!
1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.`
3. A 20% chance in this research. July 2013.
4. Dementia Risk Doubled in Patients Following Stroke September 2018
The latest here:
Blood biomarker may help estimate dementia risk in cognitively healthy adults
By Chiu Chea Liow - A blood test for phosphorylated tau 217 (p-tau217), an Alzheimer’s disease biomarker, may help estimate the 5- to 10-year risk of mild cognitive impairment (MCI) or dementia in cognitively healthy people, according to a Mayo Clinic study published in JAMA Neurology.
The approach combines p-tau217 levels with age, sex, and genetic risk.
Higher p-tau217 levels and older age were associated with greater risk. "The goal is to provide a personalised estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology," said Alicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester, Minnesota.
Alzheimer's disease pathology can be detected years before symptoms, but some biomarker-positive, cognitively unimpaired individuals remain asymptomatic. The study builds on earlier Mayo Clinic work that used PET brain scans of amyloid to predict future impairment. A blood biomarker is less invasive and potentially more scalable.
The researchers analysed 1,644 participants from the Mayo Clinic Study of Aging (MCSA) and 534 from the Alzheimer's Disease Neuroimaging Initiative (ADNI). All were cognitively unimpaired and aged 60 to 90 years, with baseline plasma p-tau217 measurements, apolipoprotein E (APOE) genotyping, and longitudinal follow-up. Transitions to MCI and dementia were estimated using continuous-time multistate models. The MCSA data were used to estimate absolute risks, and the ADNI data to confirm the association.
A p-tau217 level of 0.324 pg/mL versus 0.072 pg/mL (90th vs 10th percentile) was associated with a 2.62-fold to 3.02-fold greater hazard of clinical progression across MCSA subgroups defined by sex and APOE epsilon 4 status. In ADNI, the corresponding range was 2.08-fold to 3.99-fold. At age 75 years, the 5-year absolute risk of MCI rose from 7% (95% confidence interval [CI], 5%-8%) to 17% (95% CI, 13%-20%) for those levels, and the 10-year risk rose from 15% to 35% (P < .001 for both). At 0.324 pg/mL, the 5-year MCI risk increased from 6% at age 65 years to 37% at age 85 years. After accounting for p-tau217, APOE epsilon 4 status had only a modest association.
"A person may want to know: What is my risk of developing cognitive impairment in the next five or 10 years, and how does this blood test change that risk?" said Ronald Petersen, MD, Mayo Clinic, Rochester, Minnesota. He said such numbers could become important in treatment decisions if preventive therapies prove effective.
Clifford Jack Jr., MD, Mayo Clinic, Rochester, Minnesota, said that "absolute risk gives the biomarker result clinical context."
The authors noted that the estimates were developed in the MCSA and need further study in more diverse populations and with other p-tau217 blood tests. Alzheimer's biomarker testing is not currently recommended for people without cognitive symptoms.
Reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2856722
SOURCE: Mayo Clinic
No comments:
Post a Comment